Page last updated: 2024-12-07
4-carbamoylimidazolium 5-olate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-carbamoylimidazolium 5-olate: purine antagonist; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
5-hydroxyimidazole-4-carboxamide : A hydroxyimidazole that is 5-hydroxyimidazole in which the hydrogen at position 4 is replaced by an aminocarbonyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 124343 |
| CHEMBL ID | 4303691 |
| CHEBI ID | 88290 |
| SCHEMBL ID | 3025277 |
| SCHEMBL ID | 13219030 |
| MeSH ID | M0104540 |
Synonyms (51)
| Synonym |
|---|
| AC-7529 |
| 5-hydroxy-1h-imidazole-4-carboxamide |
| 1h-imidazole-4-carboxamide, 5-hydroxy- |
| nsc-266026 |
| 56973-26-3 |
| nsc266026 |
| sm-108 |
| 5-hydroxyimidazole 4-carboxamide |
| 4-carbamoylimidazolium 5-olate |
| 3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-alpha-ol, decahydro-3,6,9-trimethyl-, propionate (ester) |
| sm 108 |
| alpha-propionyl-dihydroartemether |
| 5-hydroxy-3h-imidazole-4-carboxylic acid amide |
| 4-hydroxy-1h-imidazole-5-carboxamide |
| AKOS006287688 |
| AKOS015917867 |
| unii-u6iz97918f |
| nsc 266026 |
| u6iz97918f , |
| FT-0630153 |
| 4-carbamoyl-5-hydroxyimidazole |
| bredinin aglycone |
| SCHEMBL3025277 |
| 4-carbamoyl-imidazolium-5-olate |
| 4-carbamoylimidazolium-5-olate |
| 4-carbamoylimidazolium-5 olate |
| UEWSIIBPZOBMBL-UHFFFAOYSA-N |
| mfcd06797616 |
| SCHEMBL13219030 |
| mizoribine aglycone |
| CHEBI:88290 |
| 5-hydroxyimidazole-4-carboxamide |
| 4(5)-hydroxy-5(4)-imidazolecarboxamide |
| mizoribine base |
| 5-hydroxy-3h-imidazole-4-carboxamide |
| DTXSID60205574 |
| J-517594 |
| Q27160166 |
| CS-0024727 |
| HY-106048 |
| DS-10728 |
| AMY15291 |
| 5-hydroxy-1h-imidazole-4-carboxamide inverted exclamation mark inverted exclamation mark |
| ff-10501-01 |
| CHEMBL4303691 |
| 5-hydroxy-1h-imidazole-4-carboxamide;sm-108 |
| 56973-26-3 (free base) |
| un5-hydroxy-1h-imidazole-4-carboxamide |
| ff-10501 |
| EN300-221830 |
| Z1198170628 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phase I study with a new oral purine antagonist, SM-108, was conducted in a total of 73 cases in a 5-day consecutive schedule with the dosage ranging from 20-2,500 mg/m2 at II institutes." | ( [Phase I study and early phase II of SM-108 (4-carbamoylimidazolium-5-olate) in lung cancer. SM-108 Study Group]. Kimura, K; Miyazaki, T; Ogawa, M; Ohno, R; Ota, K; Sakai, Y; Suzuoki, Y; Uzuka, Y; Yamada, K; Yoshida, T, 1989) | 0.28 |
| " The duration of drug action was short, and the daily dosage required adjustment at frequent intervals." | ( [Clinical trial of SM-108 in myeloproliferative disorders]. Katayama, N; Kobayashi, T; Minami, N; Morita, K; Mukai, K; Nishikawa, M; Sekine, T; Takeda, M; Tamaki, S; Tanaka, H, 1987) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (2)
| Class | Description |
|---|---|
| monocarboxylic acid amide | A carboxamide derived from a monocarboxylic acid. |
| hydroxyimidazole | Any member of the class of imidazoles in which the imidazole ring is substituted by one or more hydroxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (91.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (25.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||